Sanofi commits ‘at least $20bn’ to US manufacturing through 2030

Robert Barrie

Thu, May 15, 2025, 4:47 AM 2 min read

Sanofi has become the latest big pharma company to boost manufacturing in the US with a hefty investment as the biopharma industry safeguards itself against the continued threat of pharma tariffs from President Donald Trump.

The French drugmaker said it would commit at least $20bn in the US through 2030, with the aim to increase R&D and manufacturing capabilities.

Sanofi’s current sites in the US stand to benefit from direct investments as the company looks to enhance the robustness of its medicine supply chain amid an uncertain trade landscape.

There are 83,000 people employed by Sanofi worldwide – 13,000 of whom are based in the US. While the vaccine maker has not publicly disclosed the exact size of its US manufacturing and R&D footprint, its website lists six major locations across three states.

Sanofi’s innovation hub, which employs 2,500 people, is based in Cambridge, Massachusetts. Swiftwater, Pennsylvania contains the company’s vaccine production sites, whilst Framingham, Massachusetts houses a biologics factory. Also in Massachusetts is Sanofi’s Waltham facility, responsible for developing mRNA technology. Sanofi’s US headquarters is in Bridgewater, New Jersey.

Alongside levelling up existing sites, Sanofi stated it would expand its US presence via partnerships with other domestic manufacturers.

Sanofi’s CEO Paul Hudson said: “Our expected investments in the US will be substantial and will help ensure the production of key medicines in the US."

Companies are moving quickly to shore up US manufacturing capabilities amid tariffs implemented by Trump that have made importing certain products into the country less attractive. The biopharma industry is also bracing itself for pharmaceutical-specific tariffs, a levy continually threatened by Trump. The President signed an executive order last week that will see foreign drug manufacturing plants receive the same level of scrutiny and surprise inspections as US-based facilities, a bid to boost domestic manufacturing.

Sanofi stated that its investment decisions “will be adjusted as the external environment continues to evolve”. In 2024, $21.6bn of its $45.2bn global sales came from the US market.

Sanofi joins a long list of pharma and life science companies redirecting resources to the US in an effort to make supply chains more robust. In April, Roche unveiled a $50bn investment strategy to upgrade three R&D sites in the US. Thermo Fisher has outlaid $2bn to bolster US manufacturing, whilst Novartis, Johnson & Johnson and Eli Lilly have also made respective investment announcements in 2025. The medtech industry is also following in the same vein – Siemens Healthineers said yesterday (14 May) it would relocate manufacturing from Mexico to the US for one of its subsidiaries.